BioCentury | Oct 28, 2020
Product Development

Angelman trial pause for antisense oligo comes with efficacy data that lift Ultragenyx shares

GeneTx and Ultragenyx will look to adjust dosing and administration in their Phase I/II trial of GTX-102 to treat Angelman syndrome after patients experienced a serious adverse event thought...
BioCentury | Oct 24, 2020
Translation in Brief

UNC Chapel Hill Angelman gene therapy rescues motor function; plus data backing planned Pacylex, Kronos clinical trials and more

AAV gene editing therapy for Angelman syndromeUniversity of North Carolina at Chapel Hill scientists have created a CRISPR gene therapy for Angelman syndrome that ameliorated motor function deficits in a mouse model of the maternally...
BioCentury | Sep 30, 2020
Product Development

Sept. 29 Quick Takes: Ironwood reduces headcount following Phase III miss; plus Sandoz, Catalyst, Myovant, Orphazyme, Synklino, WHO, BridgeBio, Kurma, Junshi, Arcutis, Genfit-LabCorp and GSK

Ironwood to downsize after Phase III GERD failureIronwood Pharmaceuticals Inc. (NASDAQ:IRWD) said it plans to discontinue development of IW-3718 after the therapy missed the primary endpoint in a Phase III trial to treat refractory gastroesophageal...
BioCentury | Sep 11, 2020
Product Development

Sept. 10 Quick Takes: approvals for Zai, GSK and Phase III readouts for Satsuma, Amryt and Takeda; plus Houston Methodist, MassBio and JPM

China approves Zejula as first-line maintenance for ovarian cancerChina's National Medical Products Administration (NMPA) approved an sNDA from Zai Lab Ltd. (NASDAQ:ZLAB) for Zejula niraparib as a first-line maintenance therapy in ovarian cancer patients in...
BioCentury | Sep 10, 2020
Product Development

BioNTech, Pfizer complete exploratory talks with the European Commission for 200M COVID-19 vaccine doses

BioNTech, Pfizer vaccine to supply vaccine to EUOn Wednesday, BioNTech SE (NASDAQ:BNTX) and Pfizer Inc. (NYSE:PFE) became the sixth group of COVID-19 vaccine developers to complete exploratory talks on...
BioCentury | Sep 8, 2020
Management Tracks

Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more

Rachel Humphrey has joined Black Diamond Therapeutics Inc. (NASDAQ:BDTX) as CMO. Karsten Witt, who has been SVP of clinical development and acting CMO since May 2019, will become SVP of non-clinical development. Previously, Humphrey was...
BioCentury | Jul 11, 2020
Management Tracks

Andrews joins Akcea as CMO; plus changes at Strongbridge, Abeona, Lyra, Kronos and more

Akcea Therapeutics Inc. (NASDAQ:AKCA) said William Andrews will succeed Louis O’Dea as CMO. Andrews joins the rare disease company from Acer Therapeutics Inc. (NASDAQ:ACER), where he was CMO. Rare disease company Strongbridge Biopharma plc (NASDAQ:SBBP)...
BioCentury | Jun 19, 2020

Lyell, Pact combine T cell techs to take on solid tumors

Lyell and Pact think the union of their T cell engineering technologies could overcome the roadblocks hampering cell therapies for solid tumors. While the partners are still pursuing independent pipelines, the joint program could ultimately...
BioCentury | May 6, 2020
Management Tracks

Abrams resigns as Editas CMO; plus Immunocore, Spruce, Frazier, Horama and more

Editas Medicine Inc. (NASDAQ:EDIT) disclosed in an SEC filing that Judith Abrams resigned as CMO. The gene editing company did not immediately respond to a request for comment on its succession plans for the post....
BioCentury | Apr 28, 2020

April 27 Quick Takes: Avalyn raises $35M for fibrosis therapies, plus Actym, LifeSprout, HebeCell, Compass, Immunomic

Fibrosis company Avalyn raises $35.5M series B Seattle’s Avalyn Pharma Inc. closed a $35.5 million B round, adding to its $62 million series A in 2017. The round was led by Norwest Venture Partners with...
Items per page:
1 - 10 of 1115